Pierre Beauparlant

Pierre Beauparlant is an accomplished leader in the biomedical and life sciences sectors, currently serving as Executive Managing Director at Finchley Healthcare Ventures and Executive-in-Residence at UCSF Innovation Ventures since 2023. Previous roles include Venture Partner at Sanderling Ventures and SynLead Therapeutics Inc., and leadership positions such as President & CEO at Ovata Inc., PreciThera, Inc., and SpecificiT Pharma Inc. Pierre's career spans over two decades, with significant contributions to Novartis as Medical Therapeutic Head in Hematology and vice president of research at Gemin X Pharmaceuticals. Pierre holds a Ph.D. in Microbiology & Immunology from McGill University and an MSc in Microbiology from Université de Montréal.